Abiopharma

🔍 Wells Preston Wendell (Executive)

Company: STRYKER CORP (SYK)

Report Date: 2026-03-21

Detailed Transactions and Holdings:

• Sold 204 shares of Common Stock at $335.67 per share (Direct)
  Date: 2026-03-21 | Code: F | equity_swap_involved: 0 | shares_owned_after: 6,498.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-21 | Code: H | nature_of_ownership: 401(k) | shares_owned_after: 288.00

Footnotes:

• F1: Includes 185 shares of Stryker Common Stock acquired pursuant to Stryker Corporation's Employee Stock Purchase Plan ("ESPP") and 27 shares pursuant to the Performance Incentive Award ("PIA") Plan as of December 31, 2025, the date of the latest available statement of the reporting person's ESPP and PIA holdings.